198 related articles for article (PubMed ID: 34776964)
1. CBD Effects on Motor Profile and Neurobiological Indices Related to Glutamatergic Function Induced by Repeated Ketamine Pre-Administration.
Poulia N; Delis F; Brakatselos C; Ntoulas G; Asprogerakas MZ; Antoniou K
Front Pharmacol; 2021; 12():746935. PubMed ID: 34776964
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine.
Brakatselos C; Delis F; Asprogerakas MZ; Lekkas P; Tseti I; Tzimas PS; Petrakis EA; Halabalaki M; Skaltsounis LA; Antoniou K
Neuroscience; 2021 Feb; 454():105-115. PubMed ID: 32950556
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Kozela E; Krawczyk M; Kos T; Juknat A; Vogel Z; Popik P
Mol Neurobiol; 2020 Mar; 57(3):1733-1747. PubMed ID: 31823199
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.
Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS
Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402
[TBL] [Abstract][Full Text] [Related]
5. Advantages of the Alpha-lipoic Acid Association with Chlorpromazine in a Model of Schizophrenia Induced by Ketamine in Rats: Behavioral and Oxidative Stress evidences.
Sampaio LRL; Cysne Filho FMS; de Almeida JC; Diniz DDS; Patrocínio CFV; de Sousa CNS; Patrocínio MCA; Macêdo D; Vasconcelos SMM
Neuroscience; 2018 Mar; 373():72-81. PubMed ID: 29337238
[TBL] [Abstract][Full Text] [Related]
6. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
[TBL] [Abstract][Full Text] [Related]
7. Parvalbumin Loss Following Chronic Sub-Anesthetic NMDA Antagonist Treatment is Age-Dependent in the Hippocampus: Implications for Modeling NMDA Hypofunction.
Honeycutt JA; Chrobak JJ
Neuroscience; 2018 Nov; 393():73-82. PubMed ID: 30296474
[TBL] [Abstract][Full Text] [Related]
8. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
9. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
Osborne AL; Solowij N; Babic I; Lum JS; Newell KA; Huang XF; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109666. PubMed ID: 31202911
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
[TBL] [Abstract][Full Text] [Related]
13. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.
Becker A; Peters B; Schroeder H; Mann T; Huether G; Grecksch G
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):687-700. PubMed ID: 12787858
[TBL] [Abstract][Full Text] [Related]
14. Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice.
Szlachta M; Pabian P; Kuśmider M; Solich J; Kolasa M; Żurawek D; Dziedzicka-Wasylewska M; Faron-Górecka A
Psychopharmacology (Berl); 2017 Jul; 234(14):2103-2112. PubMed ID: 28405711
[TBL] [Abstract][Full Text] [Related]
15. Prelimbic NMDA receptors stimulation mimics the attenuating effects of clozapine on the auditory electrophysiological rebound induced by ketamine withdrawal.
Incrocci RM; Paliarin F; Nobre MJ
Neurotoxicology; 2018 Dec; 69():1-10. PubMed ID: 30170016
[TBL] [Abstract][Full Text] [Related]
16. Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Ben-Azu B; Aderibigbe AO; Ajayi AM; Eneni AO; Umukoro S; Iwalewa EO
Brain Res Bull; 2018 May; 139():292-306. PubMed ID: 29548911
[TBL] [Abstract][Full Text] [Related]
17. The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.
Mahmoud GS; Hosny G; Sayed SA
Int J Physiol Pathophysiol Pharmacol; 2021; 13(2):22-35. PubMed ID: 34093963
[TBL] [Abstract][Full Text] [Related]
18. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
Vasconcelos GS; Ximenes NC; de Sousa CN; Oliveira Tde Q; Lima LL; de Lucena DF; Gama CS; Macêdo D; Vasconcelos SM
Schizophr Res; 2015 Jul; 165(2-3):163-70. PubMed ID: 25937462
[TBL] [Abstract][Full Text] [Related]
19. Binge and Subchronic Exposure to Ketamine Promote Memory Impairments and Damages in the Hippocampus and Peripheral Tissues in Rats: Gallic Acid Protective Effects.
Brum GF; Rosa HZ; Rossato DR; Rosa JLO; Metz VG; Milanesi LH; Burger ME
Neurotox Res; 2020 Aug; 38(2):274-286. PubMed ID: 32458406
[TBL] [Abstract][Full Text] [Related]
20. Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models.
Dias KCF; de Almeida JC; Vasconcelos LC; Patrocínio MLV; Barbosa TM; Ximenes NC; Leitão APA; Louchard BO; Pimenta ATÁ; Pinto FDCL; Leal LKAM; Honório Junior JER; Vasconcelos SMM
J Pharm Pharmacol; 2019 Mar; 71(3):379-389. PubMed ID: 30456833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
